First Affiliated Hospital of Wenzhou Medical University
温州医科大学附属第一医院
Listed for 23 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at First Affiliated Hospital of Wenzhou Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌8 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌6 papers led
- Hepatocellular carcinoma肝细胞癌96 papers led2 open trials led
- Stomach cancer胃癌55 papers led3 open trials led
- Osteosarcoma骨肉瘤1 paper led
- Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
- Neuroblastoma神经母细胞瘤2 papers led
- Multiple myeloma多发性骨髓瘤6 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
- Beta thalassaemiaβ 地中海贫血2 papers led
- Haemophilia A血友病 A0 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病5 papers led
- Myasthenia gravis重症肌无力4 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化5 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病6 papers led
- Gaucher disease戈谢病0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
- Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
- Congenital diaphragmatic hernia先天性膈疝0 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led
Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Wenzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingImmune Score Based Radiomics in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2021-11
- Registry
- NCT05126160
Age 18 years to 70 years (registered criteria)
Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led8
- Optimal combination treatment for Locally Advanced Nasopharyngeal Carcinoma: A systematic review and Bayesian Network Meta-Analysis.
- The clinical value of FAPI PET/CT in delineating target volumes for nasopharyngeal carcinoma.
- Radiomics-guided generative adversarial network for automatic primary target volume segmentation for nasopharyngeal carcinoma using computed tomography images.
- Deep learning dosiomics for the pretreatment prediction of radiation dermatitis in nasopharyngeal carcinoma patients treated with radiotherapy.
- Automatic detection and recognition of nasopharynx gross tumour volume (GTVnx) by deep learning for nasopharyngeal cancer radiotherapy through magnetic resonance imaging.
- A nomogram model based on pre-treatment and post-treatment MR imaging radiomics signatures: application to predict progression-free survival for nasopharyngeal carcinoma.
- Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma - An updated meta-analysis and systematic review.
- Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)5
- 847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial
- Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.
- Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
- miRNAs Associated with Nasopharyngeal Carcinoma: New Prognostic Biomarkers and Therapeutic Targets
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 6 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wenzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- USP4-Deubiquitinated PGAM5 Regulates Mitochondrial Dynamics in the Progression of Esophageal Squamous Cell Carcinoma.
- Deep learning-based prediction of enhanced CT scans for lymph node metastasis in esophageal squamous cell carcinoma.
- Deep learning prediction of esophageal squamous cell carcinoma invasion depth from arterial phase enhanced CT images: a binary classification approach.
- Serine Protease 27, a Prognostic Biomarker in Pan-cancer and Associated with the Aggressive Progression of Breast Cancer.
- Corynoxine exerts the anti-tumor effect on esophageal squamous cell carcinoma principally via the EZH2-DUSP5-ERK1/2-mediated cell growth inhibition.
- CircRNA_101491 regulated the radiation sensitivity of esophageal squamous cell carcinomas via sponging miR-125a-5p.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 96 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.
2 hospitals in Wenzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingThe Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07381634
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingIntelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07495735
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- Not yet recruiting29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led96
- Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis.
- Development of a new nomogram for predicting recurrence in HCC with MVI following curative hepatectomy.
- Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving lenvatinib: a retrospective, multicenter cohort study.
- Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics.
- Analysis of high-risk factors for hepatocellular carcinoma after sustained virological suppression of chronic hepatitis B.
- Explainable machine learning model for predicting the transarterial chemoembolization response and subtypes of hepatocellular carcinoma patients.
- Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN.
- METTL3 inhibition promotes radiosensitivity in hepatocellular carcinoma through regulation of SLC7A11 expression.
- Disulfiram/Cu targeting FOXO6 modulates sensitivity of hepatocellular carcinoma to lenvatinib via disrupt choline metabolic.
- Melatonin reverses lenvatinib resistance in HCC by regulating the ATF4-NRF1 pathway mediated by ceramide synthase 6.
- Demethoxycurcumin induces metabolic crisis and ATF4/ATF3/CHOP-dependent cell death in hepatocellular carcinoma.
- Integrated GMPS and RAMP3 as a signature to predict prognosis and immune heterogeneity in hepatocellular carcinoma.
- Role of alphaII-spectrin and XPF interaction in Hepatocellular carcinoma.
- Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma in patients with decompensated cirrhosis.
- Visualization of protrusion-localized STAT3 mRNA using a self-powered lipidic nanoflare for predicting hepatocellular carcinoma metastasis.
- Formosanin C induces autophagy-mediated cell death in hepatocellular carcinoma through activating DUSP1/AMPK/ULK1/Beclin1 signaling pathway.
- Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma.
- Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis.
- Carfilzomib activates ER stress and JNK/p38 MAPK signaling to promote apoptosis in hepatocellular carcinoma cells.
- Does an Aspirin a Day Take the MASLD Away?
- Knockdown of ribosome RNA processing protein 15 suppresses migration of hepatocellular carcinoma through inhibiting PATZ1-associated LAMC2/FAK pathway.
- Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score.
- A novel prognostic signature and therapy guidance for hepatocellular carcinoma based on STEAP family.
- High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.
- Hepatocellular carcinoma biomarkers screening based on hydrogel photonic barcodes with tyramine deposition amplified ELISA.
- Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma.
- The significance of lipid metabolism reprogramming of tumor-associated macrophages in hepatocellular carcinoma.
- Gut Microbiota as Mediator and Moderator Between Hepatitis B Virus and Hepatocellular Carcinoma: A Prospective Study.
- ZNF300 promotes proliferation and migration of hepatocellular carcinoma by upregulating c-MYC gene expression.
- Suppressing MTERF3 inhibits proliferation of human hepatocellular carcinoma via ROS-mediated p38 MAPK activation.
- Application of artificial intelligence radiomics in the diagnosis, treatment, and prognosis of hepatocellular carcinoma.
- The involvement of ROS-regulated programmed cell death in hepatocellular carcinoma.
- Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory study.
- Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib.
- Single-cell-based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
- Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
- In vitro vascularized liver tumor model based on a microfluidic inverse opal scaffold for immune cell recruitment investigation.
- ATP citrate lyase promotes the progression of hepatocellular carcinoma by activating the REGγ-proteasome pathway.
- Crosstalk between endothelial progenitor cells and HCC through periostin/CCL2/CD36 supports formation of the pro-metastatic microenvironment in HCC.
- Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression.
- Exploration and validation of a novel signature of seven necroptosis-related genes to improve the clinical outcome of hepatocellular carcinoma.
- Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma.
- A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma.
- Matrix metalloproteinase-21 promotes metastasis via increasing the recruitment and M2 polarization of macrophages in HCC.
- Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma.
- lncRNA SNHG9 enhances liver cancer stem cell self-renewal and tumorigenicity by negatively regulating PTEN expression via recruiting EZH2.
- Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
- Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study.
- Prognostic value of combined pre- and postoperative albumin-to-alkaline phosphatase ratio for patients with hepatocellular carcinoma undergoing trans-catheter chemoembolisation.
- Targeting Hepatic Stellate Cell Death to Reverse Hepatic Fibrosis.
- Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.
- The enrichment of the gut microbiota Lachnoclostridium is associated with the presence of intratumoral tertiary lymphoid structures in hepatocellular carcinoma.
- A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.
- The utility of Vision Transformer in preoperatively predicting microvascular invasion status of hepatocellular carcinoma.
- Reflections on prediction of microvascular invasion in hepatocellular carcinoma by pathology images.
- Hypoxia-induced exosomes facilitate lung pre-metastatic niche formation in hepatocellular carcinoma through the miR-4508-RFX1-IL17A-p38 MAPK-NF-κB pathway.
- A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
- Rational Design of Gd-DOTA-Type Contrast Agents for Hepatobiliary Magnetic Resonance Imaging.
- Characterization of neutrophil extracellular traps related gene pair for predicting prognosis in hepatocellular carcinoma.
- Glycolysis-Related Gene Signature Can Predict Survival and Immune Status of Hepatocellular Carcinoma.
- A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
- M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
- The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.
- Role of ferroptosis in gastrointestinal tumors: From mechanisms to therapies.
- LncRNA HEPFAL accelerates ferroptosis in hepatocellular carcinoma by regulating SLC7A11 ubiquitination.
- The Expressions and Functions of lncRNA Related to m6A in Hepatocellular Carcinoma from a Bioinformatics Analysis.
- Identification and Validation of Hub Genes Predicting Prognosis of Hepatocellular Carcinoma.
- Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study.
- Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
- Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.
- Impact of sarcopenia on outcomes of patients undergoing liver resection for hepatocellular carcinoma.
- CAFs-derived SCUBE1 promotes malignancy and stemness through the Shh/Gli1 pathway in hepatocellular carcinoma.
- miRNA-432 and SLC38A1 as Predictors of Hepatocellular Carcinoma Complicated with Alcoholic Steatohepatitis.
- Signature Construction and Molecular Subtype Identification Based on Pyroptosis-Related Genes for Better Prediction of Prognosis in Hepatocellular Carcinoma.
- Construction of a Metabolism-Related Long Non-Coding RNAs-Based Risk Score Model of Hepatocellular Carcinoma for Prognosis and Personalized Treatment Prediction.
- Development and validation of a nomogram for predicting the cancer-specific survival of fibrolamellar hepatocellular carcinoma patients.
- Liposomes co-loaded with ursolic acid and ginsenoside Rg3 in the treatment of hepatocellular carcinoma.
- A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma.
- Identification and validation of a glycolysis-associated multiomics prognostic model for hepatocellular carcinoma.
- Letter: Hepatitis B and MAFLD - a consilience of risk factors for hepatocellular carcinoma.
- LncRNA AIRN influences the proliferation and apoptosis of hepatocellular carcinoma cells by regulating STAT1 ubiquitination.
- Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy.
- Development and Evaluation of Nomograms to Predict the Cancer-Specific Mortality and Overall Mortality of Patients with Hepatocellular Carcinoma.
- Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.
- A signature of 13 autophagy‑related gene pairs predicts prognosis in hepatocellular carcinoma.
- Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
- The value of preoperative systemic immune-inflammation index in predicting vascular invasion of hepatocellular carcinoma: a meta-analysis.
- FGF21 in obesity and cancer: New insights.
- BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism.
- Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.
- Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients.
- A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma.
- ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis.
- A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.
- Identification of Biomarkers Based on Bioinformatics Analysis: The Expression of Ubiquitin-Conjugating Enzyme E2T (UBE2T) in the Carcinogenesis and Progression of Hepatocellular Carcinoma.
- Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
All its trials on ClinicalTrials.gov, any status16
- Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
- The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
- Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies
- Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments
- Relationship Between Liver Cancer and Sarcopenia
- Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)
- Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
- Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
Cancer
Stomach cancer
胃癌Led 55 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.
3 hospitals in Wenzhou for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSingle-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
- Phase
- N/A
- Started
- 2025-11
- Registry
- NCT07586384
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- Not yet recruitingClinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2026-09
- Registry
- NCT07394205
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou
- Not yet recruitingSafety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07828899
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital of Wenzhou Medical University; 2 listed hospitals as study sitesJinan, Shijiazhuang, Wenzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led55
- CT-based delta-radiomics nomogram to assess tumor regression grade in locally advanced gastric cancer patients following neoadjuvant chemotherapy.
- Research advancements and evaluation of multifactor-induced murine models for gastric cancer.
- CD2AP shapes a stromal reduced tumor microenvironment and contributes to immunotherapy in gastric cancer.
- Sarcopenia defined by the global leadership initiative in sarcopenia (GLIS) consensus predicts adverse postoperative outcomes in patients undergoing radical gastrectomy for gastric cancer: analysis from a prospective cohort study.
- Heterogeneity of T cells regulates tumor immunity mediated by Helicobacter pylori infection in gastric cancer.
- Machine learning assisted radiomics in predicting postoperative occurrence of deep venous thrombosis in patients with gastric cancer.
- Multi-regional feature integration on enhanced CT for lymph node metastasis prediction in gastric cancer: a novel radiomics approach.
- SNRPB promotes gastric cancer progression by regulating aberrant splicing of PUF60.
- Stair climbing outperforms gait speed in predicting postoperative outcomes in patients undergoing radical gastrectomy for gastric cancer: A prospective study.
- Muscle-specific strength is an alternative to muscle mass and grip strength for predicting outcomes in patients with gastric cancer.
- Perioperative body composition changes and their clinical implications in patients with gastric cancer undergoing radical gastric cancer surgery: a prospective cohort study.
- Human cytomegalovirus tegument protein UL23 promotes gastric cancer immune evasion by facilitating PD-L1 transcription.
- Risk factors and prognostic impact of low physical performance in elderly patients undergoing radical gastrectomy for gastric cancer.
- Body composition analysis using CT at three aspects of the lumbar third vertebra and its impact on the diagnosis of sarcopenia.
- NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer.
- Effects of esketamine on postoperative fatigue syndrome in patients after laparoscopic resection of gastric carcinoma: a randomized controlled trial.
- Prognostic value of GLIM-defined malnutrition in combination with hand-grip strength or gait speed for the prediction of postoperative outcomes in gastric cancer patients with cachexia.
- Development and validation of a machine learning-based 18F-fluorodeoxyglucose PET/CT radiomics signature for predicting gastric cancer survival.
- An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study.
- Computed tomography-based radiomics nomogram for predicting therapeutic response to neoadjuvant chemotherapy in locally advanced gastric cancer : A scale for treatment predicting.
- Characteristics and prognostic impact of cancer cachexia defined by the Asian Working Group for Cachexia consensus in patients with curable gastric cancer.
- Utilizing machine learning to integrate single-cell and bulk RNA sequencing data for constructing and validating a novel cell adhesion molecules related prognostic model in gastric cancer.
- Enhanced PSO feature selection with Runge-Kutta and Gaussian sampling for precise gastric cancer recurrence prediction.
- Comparison between AWGC-cachexia and GLIM-malnutrition in patients with gastric cancer.
- Prognostic value and association of the age-adjusted Charlson Comorbidity Index with sarcopenia within patients with gastric cancer after radical resection.
- Correlation Between Basal Metabolic Rate and Clinical Outcomes in Gastric Cancer Patients: A Retrospective Study.
- Integrated multi-omics analysis and machine learning developed a prognostic model based on mitochondrial function in a large multicenter cohort for Gastric Cancer.
- Muscle attenuation, not skeletal muscle index, is an independent prognostic factor for survival in gastric cancer patients with overweight and obesity.
- Predictive nomogram for lymph node metastasis and survival in gastric cancer using contrast-enhanced computed tomography-based radiomics: a retrospective study.
- miR-325-3p Reduces Proliferation and Promotes Apoptosis of Gastric Cancer Cells by Inhibiting Human Antigen R.
- Lactate Dehydrogenase and Risk of Readmission with Gastric Cancer: A Propensity Score Matching Analysis.
- Evaluation the benefits of additional radiotherapy for gastric cancer patients after D2 resection using CT based radiomics.
- Cachexia Versus Sarcopenia in Clinical Characteristics and Prognostic Value After Radical Gastrectomy for Gastric Cancer: A Large-Scale Prospective Study.
- ASO Author Reflections: Comparison of Sarcopenia and Cachexia for Their Prognostic Value in Gastric Cancer Patients at Different TNM Stages After Gastrectomy.
- Integration of clinical and transcriptomics reveals programming of the lipid metabolism in gastric cancer.
- NF-κB-Related Metabolic Gene Signature Predicts the Prognosis and Immunotherapy Response in Gastric Cancer.
- Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition.
- Bioinformatics Analysis Revealing the Correlation between NF-κB Signaling Pathway and Immune Infiltration in Gastric Cancer.
- Global leadership initiative in malnutrition (GLIM) criteria using hand-grip strength adequately predicts postoperative complications and long-term survival in patients underwent radical gastrectomy for gastric cancer.
- Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo.
- Impact of malnutrition diagnosed using Global Leadership Initiative on Malnutrition criteria on clinical outcomes of patients with gastric cancer.
- Effect of Short-Term Preoperative Parenteral Nutrition Support for Gastric Cancer Patients with Sarcopenia: a Propensity Score Matching Analysis.
- Association of Sarcopenia and Low Nutritional Status with Unplanned Hospital Readmission after Radical Gastrectomy in Patients with Gastric Cancer: A Case-Control Study.
- Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis.
- Genotyping Helicobacter pylori antibiotic resistance and virulence-associated genes in patients with gastric cancer in Wenzhou, China.
- Prognostic value of small mother against decapentaplegic expression in human gastric cancer.
- Value of muscle quality, strength and gait speed in supporting the predictive power of GLIM-defined malnutrition for postoperative outcomes in overweight patients with gastric cancer.
- Influence of body composition, muscle strength, and physical performance on the postoperative complications and survival after radical gastrectomy for gastric cancer: A comprehensive analysis from a large-scale prospective study.
- Sarcopenia is a predictive factor of poor quality of life and prognosis in patients after radical gastrectomy.
- The relationship between the GLIM-defined malnutrition, body composition and functional parameters, and clinical outcomes in elderly patients undergoing radical gastrectomy for gastric cancer.
- Patterns of immune infiltration in gastric cancer and their clinical significance.
- Identification of lncRNA-associated competing endogenous RNA networks for occurrence and prognosis of gastric carcinoma.
- C-Myc-activated long non-coding RNA LINC01050 promotes gastric cancer growth and metastasis by sponging miR-7161-3p to regulate SPZ1 expression.
- Laparoscopic versus open resection for elderly patients with gastric cancer: a double-center study with propensity score matching method.
- Measurement of muscle quantity/quality has additional predictive value for postoperative complications and long-term survival after gastrectomy for gastric cancer in patients with probable sarcopenia as defined by the new EWGSOP2 consensus:
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status10
- Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
- Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
- Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
- Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
Cancer
Osteosarcoma
骨肉瘤Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Wenzhou for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)5
- Overexpression of hsa_circ_0136666 predicts poor prognosis and initiates osteosarcoma tumorigenesis through miR-593-3p/ZEB2 pathway.
- Piperlongumine induces apoptosis and G2/M phase arrest in human osteosarcoma cells by regulating ROS/PI3K/Akt pathway.
- Salidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2/STAT3 signaling pathway.
- MicroRNA-203 inhibits proliferation and invasion, and promotes apoptosis of osteosarcoma cells by targeting Runt-related transcription factor 2.
- CXCR7 maintains osteosarcoma invasion after CXCR4 suppression in bone marrow microenvironment.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wenzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Analysis of Potential Circular RNAs in Regulating Imatinib Resistance of Gastrointestinal Stromal Tumor.
- The correlation of sarcopenia and adverse events of imatinib therapy postoperatively in gastrointestinal stromal tumor through computed tomography quantitative body composition.
- Establishment and Verification of a Nomogram for Predicting Survival in Patients with Small Intestinal Gastrointestinal Stromal Tumors.
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Wenzhou for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
2 hospitals in Wenzhou for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 10
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-02
- Registry
- NCT07258511
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07555938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingComparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2024-08
- Registry
- NCT06520176
Age 18 years to 75 years (registered criteria)
Led by Affiliated People's Hospital of Ningbo University; 6 listed hospitals as study sitesHangzhou, Ningbo, Taizhou, Wenzhou
- RecruitingA Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-10
- Registry
- NCT06049290
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Phase
- Phase 3
- Started
- 2022-09
- Registry
- NCT05243797
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingHuman BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT05594797
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Wenzhou
- RecruitingA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05623020
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan
- RecruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Phase
- Phase 3
- Started
- 2021-10
- Registry
- NCT05020236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation.
- Genetic association between coffee consumption and multiple myeloma mediated by plasma metabolites: a Mendelian randomization study.
- Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma.
- Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.
- Matrine induces autophagic cell death by triggering ROS/AMPK/mTOR axis and apoptosis in multiple myeloma.
- Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status26
- Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China
- A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
- BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
- A Study of Daratumumab
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wenzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
- NSUN2 promotes leukemogenesis by ferritin heavy chain 1-mediated anti-ferroptosis and enhancing global protein synthesis in an m5C-dependent manner in B-acute lymphoblastic leukemia.
- Interaction between CD9 and PI3K‑p85 activates the PI3K/AKT signaling pathway in B‑lineage acute lymphoblastic leukemia.
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Beta thalassaemia
β 地中海贫血Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wenzhou for beta thalassaemia133 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
- A retrospective analysis of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation for transfusion-dependent β-thalassemia: focus on T and B lymphocyte reconstitution.
- Double-unit unrelated cord blood transplantation for thalassemia major: Comparison with HLA-identical sibling bone marrow transplantation.
Blood disorders
Haemophilia A
血友病 ALed no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wenzhou for haemophilia A132 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 5 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Wenzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- High-Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies-A Real-World Study.
- Effects of early intervention in neuromyelitis optica spectrum disorder patients with seropositive AQP4 antibodies.
- The relationship between neuromyelitis optica spectrum disorder and autoimmune diseases.
- Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders.
- Intravenous immunoglobulin as the rescue treatment in NMOSD patients.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Myasthenia gravis
重症肌无力Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wenzhou for myasthenia gravis89 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial.
- Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect.
- The Potential Implications of Neutrophil to Albumin Ratio for Short-term Prognosis in Myasthenia Gravis Patients.
- Dynamic changes of peripheral inflammatory markers link with disease severity and predict short-term poor outcome of myasthenia gravis.
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wenzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 5 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.5%.
- Open trials led
- 0
- recruiting or about to
4 hospitals in Wenzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- Decoding tamoxifen on idiopathic pulmonary fibrosis: integrating network toxicology and multi-omics.
- Fibrotic extracellular matrix microenvironment induces alveolar type II epithelial cell senescence via integrin-β1/FAK/YAP signaling pathway.
- Demethyleneberberine ameliorates pulmonary fibrosis by inhibiting the NLRP3 inflammasome and the epithelial-mesenchymal transition.
- Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.
- WSB1, a Hypoxia-Inducible E3 Ligase, Promotes Myofibroblast Accumulation and Attenuates Alveolar Epithelial Regeneration in Mouse Lung Fibrosis.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status3
- Anlotinib Capsules in the Treatment for IPF/PF-ILDs
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wenzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led5
- Fighting Amyotrophic Lateral Sclerosis by Protecting the Liver? A Prospective Cohort Study.
- Prediagnosis Insights Into Amyotrophic Lateral Sclerosis: Clinical Symptoms and Medication Use.
- Analysis of retinal markers and incident amyotrophic lateral sclerosis: An optical coherence tomography-based cohort study.
- Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients.
- Metabolic Syndrome and Risk of Amyotrophic Lateral Sclerosis: Insights from a Large-Scale Prospective Study.
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Wenzhou for Behçet disease139 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
IgA nephropathy
IgA 肾病Led 6 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Wenzhou for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- Impact of intrarenal arterial lesions on prognosis of IgA nephropathy: insights from a retrospective cohort study.
- An enhanced machine learning approach for effective prediction of IgA nephropathy patients with severe proteinuria based on clinical data.
- Clinical Significance of Persistent Hematuria Degrees in Primary IgA Nephropathy: A Propensity Score-Matched Analysis of a 10-Year Follow-Up Cohort.
- Clinical significance of intrarenal vascular lesions in non-hypertensive patients with IgA nephropathy.
- Clinical significance of massive proteinuria in primary IgA nephropathy with and without nephrotic syndrome: a single center cohort study.
- Clinicopathological and prognostic study of IgA-dominant postinfectious glomerulonephritis.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)5
- Association between lifestyle, gender and risk for developing end-stage renal failure in IgA nephropathy: a case-control study within 10 years.
- Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study.
- Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.
- Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study.
- Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Gaucher disease
戈谢病Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wenzhou for Gaucher disease40 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Wenzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wenzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)3
- Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.
- Localized intrahepatic IgG4-related sclerosing cholangitis (IgG4-SC) as an additional type of IgG4-SC: a systematic analysis of 12 cases.
- The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wenzhou for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wenzhou for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other linked evidence
Getting in touch
Name card to show staff or a driver
温州医科大学附属第一医院
First Affiliated Hospital of Wenzhou Medical University
温州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
First Affiliated Hospital of Wenzhou Medical University Wenzhou; First affiliated hospital of Wenzhou medical University; First Affiliated Hospital of Wenzhou Medical College; First Affiliated Hospital of Wenzhou Medical Uinversity; First Provincial Wenzhou Hospital of Zhejiang